A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
Part of paid clinical trials in Plantation, Florida.
- Sponsor
- UCB Biopharma SRL
- Study ID
- NCT07720375
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Non-cystic Fibrosis Bronchiectasis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Galvokimig — BIOLOGICALDrug: Galvokimig Pharmaceutical form: Solution for injection
- Placebo — BIOLOGICALDrug: Placebo Pharmaceutical form: Solution for injection
Study Details
The purpose of the study is to investigate the efficacy of galvokimig versus placebo on the time to the first pulmonary exacerbation in study participants with non-cystic fibrosis bronchiectasis (NCFB)
Key Dates
- First listed
- Jul 22, 2026
- Start date
- Aug 5, 2026
- Status verified
- Aug 2026
- Primary completion
- Feb 28, 2029
- Completion
- Apr 26, 2029
Study Design
- Enrollment
- 300 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Galvokimig Dose 1 ArmParticipants randomly assigned to this arm will receive Galvokimig Dose 1
- Experimental: Galvokimig Dose 2 ArmParticipants randomly assigned to this arm will receive Galvokimig Dose 2
- Experimental: Galvokimig Dose 3 ArmParticipants randomly assigned to this arm will receive Galvokimig Dose 3
- Placebo Comparator: Placebo ArmParticipants randomly assigned to this arm will receive a matching Placebo.
Primary Outcome Measure
Time from intervention assignment to first moderate or severe pulmonary exacerbation [ Time Frame: Up to Week 52 ]
Central Contacts
- UCB Cares1-844-599-2273 (USA)
- UCB Cares0018445992273
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Ncfb01 50005 | Plantation | Florida | 33324-7006 | - |
| Ncfb01 50004 | DuBois | Pennsylvania | 15801 | - |
| Ncfb01 50001 | McKinney | Texas | 75069 | - |
Find similar trials in Plantation, FL
Related Studies
- Breathing Training and Exercise Capacity in Non-CFBRecruiting · Mayo Clinic · Jacksonville, Florida
- A Phase II Study of Ensifentrine in Non-Cystic Fibrosis BronchiectasisPHASE2 · Recruiting · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA · Birmingham, Alabama
- A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive DiseasePHASE1 · Recruiting · Genentech, Inc. · Birmingham, Alabama
- A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. AeruginosaPHASE1 · Recruiting · Revagenix, Inc. · Miami, Florida